A small molecule inhibitor of Rheb selectively targets mTORC1 signaling.Mahoney, S.J., Narayan, S., Molz, L., Berstler, L.A., Kang, S.A., Vlasuk, G.P., Saiah, E.
(2018) Nat Commun 9: 548-548
- PubMed: 29416044
- DOI: https://doi.org/10.1038/s41467-018-03035-z
- Primary Citation of Related Structures:
5YXH, 6BSX, 6BT0
- PubMed Abstract:
The small G-protein Rheb activates the mechanistic target of rapamycin complex 1 (mTORC1) in response to growth factor signals. mTORC1 is a master regulator of cellular growth and metabolism; aberrant mTORC1 signaling is associated with fibrotic, metabolic, and neurodegenerative diseases, cancers, and rare disorders. Point mutations in the Rheb switch II domain impair its ability to activate mTORC1. Here, we report the discovery of a small molecule (NR1) that binds Rheb in the switch II domain and selectively blocks mTORC1 signaling. NR1 potently inhibits mTORC1 driven phosphorylation of ribosomal protein S6 kinase beta-1 (S6K1) but does not inhibit phosphorylation of AKT or ERK. In contrast to rapamycin, NR1 does not cause inhibition of mTORC2 upon prolonged treatment. Furthermore, NR1 potently and selectively inhibits mTORC1 in mouse kidney and muscle in vivo. The data presented herein suggest that pharmacological inhibition of Rheb is an effective approach for selective inhibition of mTORC1 with therapeutic potential.
Navitor Pharmaceuticals, Inc., 1030 Massachusetts Ave. #410, Cambridge, MA, 02138, USA. firstname.lastname@example.org.